393 related articles for article (PubMed ID: 16799554)
1. Coupling ligand structure to specific conformational switches in the beta2-adrenoceptor.
Yao X; Parnot C; Deupi X; Ratnala VR; Swaminath G; Farrens D; Kobilka B
Nat Chem Biol; 2006 Aug; 2(8):417-22. PubMed ID: 16799554
[TBL] [Abstract][Full Text] [Related]
2. Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes.
Katritch V; Reynolds KA; Cherezov V; Hanson MA; Roth CB; Yeager M; Abagyan R
J Mol Recognit; 2009; 22(4):307-18. PubMed ID: 19353579
[TBL] [Abstract][Full Text] [Related]
3. Molecular dynamics simulations of the effect of the G-protein and diffusible ligands on the β2-adrenergic receptor.
Goetz A; Lanig H; Gmeiner P; Clark T
J Mol Biol; 2011 Dec; 414(4):611-23. PubMed ID: 22037586
[TBL] [Abstract][Full Text] [Related]
4. Ligand-specific interactions modulate kinetic, energetic, and mechanical properties of the human β2 adrenergic receptor.
Zocher M; Fung JJ; Kobilka BK; Müller DJ
Structure; 2012 Aug; 20(8):1391-402. PubMed ID: 22748765
[TBL] [Abstract][Full Text] [Related]
5. Agonist-induced conformational changes in bovine rhodopsin: insight into activation of G-protein-coupled receptors.
Bhattacharya S; Hall SE; Vaidehi N
J Mol Biol; 2008 Oct; 382(2):539-55. PubMed ID: 18638482
[TBL] [Abstract][Full Text] [Related]
6. Understanding the effects on constitutive activation and drug binding of a D130N mutation in the β2 adrenergic receptor via molecular dynamics simulation.
Zhu Y; Yuan Y; Xiao X; Zhang L; Guo Y; Pu X
J Mol Model; 2014 Nov; 20(11):2491. PubMed ID: 25342155
[TBL] [Abstract][Full Text] [Related]
7. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor.
Bokoch MP; Zou Y; Rasmussen SG; Liu CW; Nygaard R; Rosenbaum DM; Fung JJ; Choi HJ; Thian FS; Kobilka TS; Puglisi JD; Weis WI; Pardo L; Prosser RS; Mueller L; Kobilka BK
Nature; 2010 Jan; 463(7277):108-12. PubMed ID: 20054398
[TBL] [Abstract][Full Text] [Related]
8. Ligand-stabilized conformational states of human beta(2) adrenergic receptor: insight into G-protein-coupled receptor activation.
Bhattacharya S; Hall SE; Li H; Vaidehi N
Biophys J; 2008 Mar; 94(6):2027-42. PubMed ID: 18065472
[TBL] [Abstract][Full Text] [Related]
9. Allosteric nanobodies reveal the dynamic range and diverse mechanisms of G-protein-coupled receptor activation.
Staus DP; Strachan RT; Manglik A; Pani B; Kahsai AW; Kim TH; Wingler LM; Ahn S; Chatterjee A; Masoudi A; Kruse AC; Pardon E; Steyaert J; Weis WI; Prosser RS; Kobilka BK; Costa T; Lefkowitz RJ
Nature; 2016 Jul; 535(7612):448-52. PubMed ID: 27409812
[TBL] [Abstract][Full Text] [Related]
10. Identifying conformational changes of the beta(2) adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators.
Reynolds KA; Katritch V; Abagyan R
J Comput Aided Mol Des; 2009 May; 23(5):273-88. PubMed ID: 19148767
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Prediction of G-Protein-Coupled Receptor Ligand Function: A β-Adrenoceptor Case Study.
Kooistra AJ; Leurs R; de Esch IJ; de Graaf C
J Chem Inf Model; 2015 May; 55(5):1045-61. PubMed ID: 25848966
[TBL] [Abstract][Full Text] [Related]
12. Adrenaline-activated structure of β2-adrenoceptor stabilized by an engineered nanobody.
Ring AM; Manglik A; Kruse AC; Enos MD; Weis WI; Garcia KC; Kobilka BK
Nature; 2013 Oct; 502(7472):575-579. PubMed ID: 24056936
[TBL] [Abstract][Full Text] [Related]
13. Fluorescent labeling of purified beta 2 adrenergic receptor. Evidence for ligand-specific conformational changes.
Gether U; Lin S; Kobilka BK
J Biol Chem; 1995 Nov; 270(47):28268-75. PubMed ID: 7499324
[TBL] [Abstract][Full Text] [Related]
14. Distinct interactions of human beta1- and beta2-adrenoceptors with isoproterenol, epinephrine, norepinephrine, and dopamine.
Weitl N; Seifert R
J Pharmacol Exp Ther; 2008 Dec; 327(3):760-9. PubMed ID: 18772317
[TBL] [Abstract][Full Text] [Related]
15. Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor.
Gether U; Lin S; Ghanouni P; Ballesteros JA; Weinstein H; Kobilka BK
EMBO J; 1997 Nov; 16(22):6737-47. PubMed ID: 9362488
[TBL] [Abstract][Full Text] [Related]
16. Simulations of biased agonists in the β(2) adrenergic receptor with accelerated molecular dynamics.
Tikhonova IG; Selvam B; Ivetac A; Wereszczynski J; McCammon JA
Biochemistry; 2013 Aug; 52(33):5593-603. PubMed ID: 23879802
[TBL] [Abstract][Full Text] [Related]
17. Structure of a nanobody-stabilized active state of the β(2) adrenoceptor.
Rasmussen SG; Choi HJ; Fung JJ; Pardon E; Casarosa P; Chae PS; Devree BT; Rosenbaum DM; Thian FS; Kobilka TS; Schnapp A; Konetzki I; Sunahara RK; Gellman SH; Pautsch A; Steyaert J; Weis WI; Kobilka BK
Nature; 2011 Jan; 469(7329):175-80. PubMed ID: 21228869
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for ligand binding and specificity in adrenergic receptors: implications for GPCR-targeted drug discovery.
Huber T; Menon S; Sakmar TP
Biochemistry; 2008 Oct; 47(42):11013-23. PubMed ID: 18821775
[TBL] [Abstract][Full Text] [Related]
19. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function.
Rosenbaum DM; Cherezov V; Hanson MA; Rasmussen SG; Thian FS; Kobilka TS; Choi HJ; Yao XJ; Weis WI; Stevens RC; Kobilka BK
Science; 2007 Nov; 318(5854):1266-73. PubMed ID: 17962519
[TBL] [Abstract][Full Text] [Related]
20. Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists.
Swaminath G; Deupi X; Lee TW; Zhu W; Thian FS; Kobilka TS; Kobilka B
J Biol Chem; 2005 Jun; 280(23):22165-71. PubMed ID: 15817484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
